Cancer news - the latest biotech news from Labiotech.eu

Home Cancer Page 29

Latest Posts

Valo Therapeutics

News and Trends 20 Dec 2022

Watch: Valo Therapeutics at Bio-Europe

Valo Therapeutics Oy is a Finnish immunotherapy company developing antigen-coated oncolytic viruses and vaccine vectors as innovative immunotherapy approaches against cancer and infectious disease. The Valo Therapeutics lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed at the laboratory of Vincenzo Cerullo at the University of Helsinki in Finland. It turns oncolytic adenoviruses into targeted […]

December 20, 2022 - 1 minutemin - By Jim Cornall

malmomassan Malmö

News and Trends 20 Dec 2022

Watch: Mendus interview

Mendus AB is a Swedish company dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. The company leverages its expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy […]

December 20, 2022 - 3 minutesmins - By Jim Cornall

solid tumor tumour

News and Trends 20 Dec 2022

Ori Biotech and Inceptor Bio partner on solid tumor cell therapy

Cell and gene therapy (CGT) company Ori Biotech, and cell therapy firm Inceptor Bio have announced a new partnership. The deal will utilize Ori Biotech’s manufacturing platform technology to support initial process development through scale-up for manufacturing of Inceptor’s novel CAR-M, CAR-T and CAR-NK programs. Inceptor Bio is the third partner to join Ori’s LightSpeed […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

Pancreatic Cancer

News and Trends 20 Dec 2022

iOnctura raises €17.5M for pancreatic cancer therapy

iOnctura BV, a clinical-stage biotech developing novel cancer therapies, has been granted €17.5 million ($18.6 million) funding from the European Investment Council’s (EIC) accelerator program to develop IOA-289 for pancreatic cancer. The EIC’s funding consists of a grant of €2.5 million ($2.7 million), and €15 million ($16 million) of equity investment. Earlier this month, iOnctura […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

bladder cancer

News and Trends 19 Dec 2022

UroGen completes bladder cancer phase 3 trial enrollment

UroGen Pharma Ltd. says its phase 3 ENVISION study of investigational agent UGN-102 (mitomycin) for intravesical solution in development for the treatment of LG-IR-NMIBC is fully enrolled. The study targeted enrollment of 220 patients across 90 sites and, assuming positive findings, UroGen anticipates submitting a New Drug Application (NDA) for UGN-102 in 2024. “Completing enrollment […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

acute myeloid leukaemia leukemia AML

News and Trends 19 Dec 2022

Ordaōs and Yatiri Bio to tackle AML

Ordaōs has announced a joint development agreement to create new therapeutics for two novel targets in acute myeloid leukemia (AML) with Yatiri Bio. Ordaōs is a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, and Yatiri Bio is a biotechnology company that has developed a proprietary platform that links patient proteomic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT

M&A Mergers and acquisitions

News and Trends 19 Dec 2022

Prenetics acquires ACT Genomics

Prenetics Global Limited is acquiring a majority stake in ACT Genomics Holdings Company Limited, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and in the U.K. “With the addition of ACT’s technologies, capabilities and team, Prenetics will be well-positioned to accelerate the utilization of genetic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

shutterstock lung cancer

News and Trends 19 Dec 2022

Jacobio’s cancer treatment given breakthrough therapy designations by China CDE

Jacobio Pharma’s in-house KRAS G12C inhibitor JAB-21822 has been granted breakthrough therapy designations in China. The designations are for the second line and above treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation. The designations were granted by the Center for Drug Evaluation (CDE) of the National Medical Products […]

December 19, 2022 - 2 minutesmins - By Jim Cornall

cancer tumour tumor cells

News and Trends 19 Dec 2022

Sanofi and Innate Pharma expand natural killer cell deal

Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

cell therapy

News and Trends 19 Dec 2022

LIfT BioSciences gets a double boost

LIfT BioSciences’ is receiving more investment, and has been accepted into Johnson & Johnson Innovation’s JLABS network. LIfT BioSciences’ lead investor, Starbloom Capital, provided further investment into the company to accelerate LIfT’s R&D plans and progress N-LIfT, the company’s first-to-market anti-cancer innate cell therapy, (neutrophil only leukocyte infusion therapy) into clinical development by Q1 2024, […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

plasmid DNA

News and Trends 19 Dec 2022

Nykode Therapeutics and Richter-Helm BioLogics announce partnership

Nykode Therapeutics ASA has entered into a strategic manufacturing partnership with Richter-Helm BioLogics GmbH & Co KG to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “We are excited about the strategic manufacturing partnership with Richter-Helm BioLogics. As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

gastric cancer

News and Trends 16 Dec 2022

Astellas gastric cancer drug meets phase 3 primary endpoint

Astellas Pharma Inc. has announced positive topline results from the phase 3 GLOW clinical trial evaluating the efficacy and safety of zolbetuximab in combination with CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin). Zolbetuximab is an investigational first-in-class claudin-18.2 (CLDN18.2) targeted monoclonal antibody, for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT